From the OEHHA:
On June 27, 2008, OEHHA published two separate notices in the California Regulatory Notice Register (Register 08 No. 26-Z) soliciting information which may be relevant to the evaluation of imazalil and thiabendazole and its hypophosphite salt under consideration for possible listing within the context of the Proposition 65 administrative listing regulatory criteria in Title 27 of the California Code of Regulations section 25306 (formerly Title 22 of the California Code of Regulations section 12306.)
The publication of the notices initiated 60?day public comment periods which would have closed on August 26, 2008. OEHHA has received requests from interested parties seeking an extension of each comment period to allow for the submission of complete and relevant scientific information for both imazalil and thiabendazole and its hypophosphite salt. OEHHA hereby extends the public comment periods for imazalil and thiabendazole and its hypophosphite salt for 45 days to 5 p.m., Wednesday, October 8, 2008.
Click on the above link for more information.
Nexreg Compliance